Carbinoxamine
Histamine-1 Receptor Antagonist — RESPIRATORY SYSTEM
Also known as: carbinoxamine diphenyldisulfonate, carbinoxamine maleate, carbinoxamine tannate, paracarbinoxamine, paracarinoxamine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Carbinoxamine is an ofp drug in the Histamine-1 Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1974. Its mechanism of action is classified as Histamine H1 Receptor Antagonists. DrugCentral lists 1 molecular target, including HRH1. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Common cold and Dermatographic urticaria.
- Approval status: ofp (first approved 1974 by the FDA).
- Drug class: Histamine-1 Receptor Antagonist.
- Mechanism of action: Histamine H1 Receptor Antagonists.
- Molecular targets: HRH1 (1 listed in DrugCentral).
- Indications: Allergic conjunctivitis, Allergic rhinitis, Common cold, Dermatographic urticaria and Itching of skin and others.
- ATC code: R06AA08 (Aminoalkyl ethers).
- Molecular formula: C16H19ClN2O; molecular weight 290.79 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (9)
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Dermatographic urticaria
- Itching of skin
- Nasal discharge
- Seasonal allergic rhinitis
- Urticaria
- Vasomotor rhinitis
Contraindications (86)
- Achalasia of esophagus
- Acidosis
- Acute abdominal pain
- Acute hepatitis
- Acute pancreatitis
- Alcohol intoxication
- Alcohol withdrawal delirium
- Angle-closure glaucoma
- Arterial thrombosis
- Arteriosclerotic vascular disease
- Asthenia
- Atony of colon
- Autonomic dysreflexia
- Benign intracranial hypertension
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Bleeding
- Bradycardia
- Brain damage
- Breastfeeding (mother)
- Central nervous system depression
- Chronic heart failure
- Chronic idiopathic constipation
- Chronic lung disease
- Coma
- Complete trisomy 21 syndrome
- Conduction disorder of the heart
- Constipation
- Cor pulmonale
- Coronary arteriosclerosis
- + 56 more
Mechanism & targets
| Mechanism of action (MoA) | Histamine H1 Receptor Antagonists |
|---|---|
| Established pharmacologic class | Histamine-1 Receptor Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Histamine H1 receptor | HRH1 | antagonist | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1974-12-27 | FDA | — | MCNEIL |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
R06AA08 | RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Aminoalkyl ethers |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Carbinoxamine is on its molecule page.
| Molecular formula | C16H19ClN2O |
|---|---|
| Molecular weight | 290.79 g/mol |
| CAS number | 486-16-8 |
| InChIKey | OJFSXZCBGQGRNV-UHFFFAOYSA-N |
| PubChem CID | 2564 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Carbinoxamine used for?
DrugCentral lists the following indications for Carbinoxamine: Allergic conjunctivitis, Allergic rhinitis, Common cold, Dermatographic urticaria, Itching of skin, Nasal discharge, Seasonal allergic rhinitis and Urticaria and others.
How does Carbinoxamine work?
Carbinoxamine is classified as Histamine H1 Receptor Antagonists; its molecular targets in DrugCentral include HRH1 (antagonist).
When was Carbinoxamine first approved?
Carbinoxamine was first approved by the FDA in 1974.
What drug class does Carbinoxamine belong to?
Carbinoxamine is in the Histamine-1 Receptor Antagonist class.
What is the chemical formula of Carbinoxamine?
Carbinoxamine has the molecular formula C16H19ClN2O and a molecular weight of 290.79 g/mol.
Browse: all drugs starting with C · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 499 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200974 — compound record and bioactivity
- PubChem CID 2564 — chemical identifiers
- DrugBank DB00748 — drug record
- FDA UNII 982A7M02H5 — substance identity
- DailyMed: FDA labels for Carbinoxamine — current prescribing information (label search)
- UniProt P35367 (HRH1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.